Diseases, Conditions, Syndromes

Vaccine narrows racial disparities in pneumococcal disease

In a major public health success, the introduction of pneumococcal conjugate vaccine PCV13, or Prevnar 13, in 2010 in the United States is associated with reduction in socioeconomic disparities and the near elimination of ...

Oncology & Cancer

Single-dose PCV13 immunogenic, safe in pediatric oncology

(HealthDay)—For pediatric and adolescent oncology patients, a single-dose 13-valent pneumococcal conjugate vaccine (PCV13) is safe and immunogenic, according to a study published online July 11 in Cancer.

Diseases, Conditions, Syndromes

Team publishes longitudinal work on pneumonia

A Marshall University Joan C. Edwards School of Medicine research team has published findings that show patients who recover from invasive pneumococcal pneumonia, on average, live 10 years less when measured against life ...

Medical research

Team uses Google analytical tool to gauge vaccine effectiveness

Using a statistical method initially developed by Google, a Yale School of Public Health-led research team has devised a novel way to better analyze the impact of vaccines. The research was published in the Proceedings of ...

Medications

Seniors need two pneumonia vaccines, CDC advisory panel says

(HealthDay)—Adults 65 and older need two vaccines to better protect them from bacterial infection in the blood (called sepsis), meningitis and pneumonia, according to a revised vaccination schedule from the 2015 Advisory ...

page 1 from 3